These Analysts Slash Their Forecasts On Century Therapeutics After Weak Q2 Results

Century Therapeutics, Inc. IPSC reported weaker-than-expected second-quarter results.

Century Therapeutics posted quarterly loss of 56 cents per share, missing analysts’ expectations for a loss of 54 cents per share. The company’s sales came in $99,000, missing estimates of $1.14 million.

Century Therapeutics shares fell 1.7% to close at $2.85 on Wednesday.

These analysts made changes to their price targets on Century Therapeutics following earnings announcement.

  • Chardan Capital cut the price target on Century Therapeutics from $19 to $17. Chardan Capital analyst Geulah Livshits maintained a Buy rating.
  • HC Wainwright & Co. lowered the price target on Century Therapeutics from $17 to $13. HC Wainwright & Co. analyst Mitchell Kapoor maintained a Buy rating on the stock.
  • EF Hutton analyst Tony Butler, meanwhile, reiterated Century Therapeutics with a Buy and maintained a $16 price target.


Read This Next: Disney, Alibaba And 3 Stocks To Watch Heading Into Thursday

Market News and Data brought to you by Benzinga APIs
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsPenny StocksPrice TargetPre-Market OutlookAnalyst RatingsTrading IdeasPT Changes
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!